Blokátory systému renin-angiotenzin-aldosteron u fibrilace síní

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Renin-angiotensin-aldosterone system blockers in atrial fibrillation
Authors

ŠPINAR Jindřich ŠPINAROVÁ Lenka

Year of publication 2011
Type Article in Periodical
Magazine / Source Remedia
MU Faculty or unit

Faculty of Medicine

Citation
Field Cardiovascular diseases incl. cardiosurgery
Keywords atrial fibrillation; atrial remodelling; upstream therapy; irbesartan; valsartan
Description Atrial fibrillation is the most common sustained arrhythmia. It is associated with increased morbidity, mortality and decreased quality of life. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce morbidity and mortality in patients with heart failure, vascular disease, and hypertension. The TRACE study demonstrated a 55% decrease of atrial fibrillation in patients with chronic heart failure treated with trandolapril. Treatment of hypertension with ACE-I or ARB shows a decrease of new oncet of atrial fibrillation by one third, which was confirmed by the LIFE study – 33% decrease of new onset of atrial fibrillation. In contrast the HOPE and TRANSCEND studies did not confirm any effect of ramipril and/or telmisartan in patients with atrial fibrillation. The ACTIVE I study tested irbesartan versus placebo in 9016 patients with atrial fibrillation. Primary endpoint – myocardial infarction, stroke and vascular death – were not different. The largest post-cardioversion study – GISSI-AF trial – did not confirm the effect on maintenance of sinus rhytm in 1442 patients after cardioversion for atrial fibrillation. The guidelines of the European Society of Cardiology for upstream therapy in atrial fibrillation are included.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.